List of Excipients in Branded Drug DIOVAN HCT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	DIOVAN HCT	valsartan and hydrochlorothiazide	0078-0314	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	DIOVAN HCT	valsartan and hydrochlorothiazide	0078-0314	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	DIOVAN HCT	valsartan and hydrochlorothiazide	0078-0314	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	DIOVAN HCT	valsartan and hydrochlorothiazide	0078-0314	HYPROMELLOSES

DIOVAN HCT Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Diovan HCT combines valsartan, an angiotensin II receptor blocker, with hydrochlorothiazide, a thiazide diuretic. Its commercial opportunity is primarily generic and lifecycle-based rather than patent-led. The strongest excipient opportunities are improved moisture protection, tablet robustness, dissolution control, swallowability, and manufacturing cost reduction while maintaining bioequivalence to the reference product.

Diovan HCT is an immediate-release, multilayer? No. It is a conventional compressed tablet available in fixed-dose strengths. Its inactive-ingredient platform includes lactose, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, talc, polyethylene glycol, hypromellose, titanium dioxide, and iron oxides, depending on strength and tablet presentation.[1]

What is Diovan HCT and how is it formulated?

Diovan HCT contains valsartan and hydrochlorothiazide in fixed combinations. U.S. strengths include:

Product strength	Valsartan	Hydrochlorothiazide	Commercial purpose
Diovan HCT 80/12.5 mg	80 mg	12.5 mg	Initial or lower-intensity combination therapy
Diovan HCT 160/12.5 mg	160 mg	12.5 mg	Common maintenance strength
Diovan HCT 160/25 mg	160 mg	25 mg	Higher diuretic intensity
Diovan HCT 320/12.5 mg	320 mg	12.5 mg	High-dose valsartan maintenance
Diovan HCT 320/25 mg	320 mg	25 mg	Maximum labeled combination strength

The product is indicated for hypertension when combination therapy is appropriate. It can also be used as add-on therapy when blood pressure is inadequately controlled with either component alone.[1]

The formulation must manage two active pharmaceutical ingredients with different dose levels, flow properties, dissolution behavior, and stability profiles. Hydrochlorothiazide is present at a relatively low dose in the 12.5 mg strengths, increasing the importance of blend uniformity and segregation control.

What excipients are used in Diovan HCT tablets?

The reference-product excipient system includes:

• Lactose monohydrate as a diluent and compressibility aid.
• Microcrystalline cellulose as a filler and dry-binding agent.
• Crospovidone as a superdisintegrant.
• Povidone as a binder.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate as a lubricant.
• Talc as a processing aid.
• Hypromellose, polyethylene glycol, and titanium dioxide in the film coating.
• Iron oxide colorants for strength identification.

The precise quantitative composition is proprietary. The qualitative list is disclosed in the U.S. prescribing information and DailyMed labeling.[1,2]

What is the optimal excipient strategy for a generic Diovan HCT product?

A generic manufacturer should treat Diovan HCT as a low-dose, two-API immediate-release formulation with moderate formulation sensitivity. The most defensible strategy is a conventional, scalable tablet platform rather than a novel delivery system.

Core tablet platform

A practical formulation architecture would use:

Formulation function	Candidate excipient classes	Development objective
Dilution	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Achieve tablet mass and acceptable compression
Binding	Povidone, copovidone, pregelatinized starch	Improve tensile strength and reduce friability
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Match dissolution and disintegration
Flow improvement	Colloidal silicon dioxide	Control hopper flow and blend uniformity
Lubrication	Magnesium stearate, sodium stearyl fumarate	Control ejection force without slowing dissolution
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protect the tablet and identify strengths

Microcrystalline cellulose and lactose offer a familiar immediate-release platform. Mannitol may create a lower-hygroscopicity, better-tasting product, but it can increase cost and alter compaction behavior. Dibasic calcium phosphate can improve mechanical strength but may introduce density and dissolution differences that require careful optimization.

Crospovidone is a logical reference excipient because rapid tablet breakup supports immediate release. Croscarmellose sodium may be a viable alternative, but its swelling mechanism can produce different disintegration and dissolution profiles. Sodium starch glycolate may be less attractive where rapid, robust dissolution is required across manufacturing scale.

Lubrication control

Magnesium stearate is commercially standard, but excessive concentration or over-blending can reduce tablet wettability and slow dissolution. A generic manufacturer should establish a narrow lubrication design space using:

• Ejection force.
• Tablet tensile strength.
• Friability.
• Disintegration time.
• Dissolution at multiple pH values.
• Blend and content uniformity.

Sodium stearyl fumarate can provide an alternative where magnesium stearate sensitivity is identified. It may support better dissolution in some formulations but can have different flow and compression behavior.

What formulation patents protect Diovan HCT?

The main U.S. patent risk for Diovan HCT is historical rather than current. The original valsartan and valsartan/hydrochlorothiazide patent estate supported Novartis commercialization, but those rights have expired or reached the end of their effective commercial life in the United States. Generic valsartan/hydrochlorothiazide products are approved through the ANDA pathway.

The relevant patent categories were:

1. Composition patents covering valsartan.
2. Combination patents covering valsartan with hydrochlorothiazide.
3. Pharmaceutical formulation patents.
4. Manufacturing and solid-form rights.
5. Method-of-use patents for hypertension treatment.

The original valsartan compound patent was U.S. Patent No. 5,399,578, assigned to Ciba-Geigy, now part of Novartis. Its U.S. patent term expired before the current generic market developed. A later combination patent estate protected valsartan/hydrochlorothiazide products, but those rights no longer create a broad U.S. entry barrier for conventional generic tablets.[3]

Patent status must be assessed by jurisdiction and patent family. Expiration dates can differ because of patent-term adjustment, patent-term extension, terminal disclaimers, national-phase prosecution, and pediatric exclusivity. The FDA Orange Book and USPTO Patent Center remain the controlling sources for current U.S. listed patent information.[4,5]

When did Diovan HCT lose exclusivity?

Diovan HCT lost practical branded exclusivity after the expiration of the relevant valsartan and combination patent rights and the launch of ANDA-approved competitors. Unlike a biologic, it has no biosimilar exclusivity framework. Its competitive exposure is governed by small-molecule generic substitution.

Exclusivity category	Diovan HCT position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	Not a current commercial barrier
Composition patent protection	Expired in the United States
Combination/formulation patent protection	No broad current barrier to conventional U.S. generic entry
ANDA market dynamics	Multiple generic competitors

The FDA approved valsartan/hydrochlorothiazide ANDAs from multiple manufacturers. Product availability varies by strength, supplier, wholesaler inventory, and procurement contract.[6]

What is the Orange Book status of Diovan HCT?

Diovan HCT is an approved small-molecule drug product listed under the valsartan and hydrochlorothiazide combination. The Orange Book records NDA and ANDA approval information and any FDA-recognized patent listings associated with the reference product.[4]

For commercial planning, the important Orange Book conclusions are:

• The product is eligible for generic substitution through ANDA approval.
• A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence.
• Current patent listings do not create the type of active, high-value barrier associated with a recently launched branded combination product.
• Paragraph IV litigation risk is materially lower than it was during the original patent term.

A manufacturer should not assume that the absence of a current broad patent barrier eliminates all litigation risk. Individual formulation, process, labeling, or jurisdiction-specific patents can still require review. The commercial question is whether any asserted right would block the proposed product, not whether any patent exists in the broader family.

What Paragraph IV challenges affect Diovan HCT?

Paragraph IV challenges were relevant during the period when Novartis asserted patents against generic valsartan/hydrochlorothiazide applicants. Today, the principal risk is regulatory execution rather than a first-wave patent injunction.

A new ANDA applicant could still make a Paragraph IV certification against any Orange Book-listed patent that remains relevant. The filing would require notice to the patent holder and could trigger Hatch-Waxman litigation. A successful suit could invoke a 30-month stay of final approval, subject to statutory exceptions.[7]

For a conventional Diovan HCT generic, the likely risk profile is:

Risk	Current assessment
Basic valsartan compound patent	Low
Historic combination patent	Low if expired
New formulation patent	Product-specific
Labeling or method-of-use dispute	Manageable through carve-out analysis
Bioequivalence failure	Moderate technical risk
Manufacturing change after approval	Moderate change-control risk
Supply interruption	Material commercial risk

What formulation improvements create commercial opportunities?

The reference product is mature, so a new entrant needs a measurable advantage in cost, supply, usability, or channel access. The strongest opportunities are incremental.

Moisture-resistant tablets

Valsartan and hydrochlorothiazide products require stability work across temperature and humidity conditions. A moisture-resistant formulation can use:

• Lower-moisture excipients.
• High-barrier film coating.
• Aluminum-aluminum blister packaging.
• Desiccant-enabled bottles.
• Optimized granulation or direct-compression processing.

The opportunity is greatest in humid markets and institutional supply contracts where stability failures, tablet discoloration, or packaging complaints create switching costs.

Lactose-free or reduced-lactose products

The reference formulation uses lactose. A lactose-free generic could target patients with lactose sensitivity and institutional buyers seeking simplified excipient declarations. The commercial value is limited because lactose intolerance does not generally make small amounts of pharmaceutical lactose clinically problematic, but a clean-label or lactose-free positioning can support selected pharmacy and international channels.

Mannitol, microcrystalline cellulose, or calcium phosphate can replace lactose, subject to dissolution and bioequivalence performance.

Low-cost direct compression

Direct compression can reduce equipment, processing time, solvent handling, and drying costs. It is attractive if the API particle-size distribution and blend uniformity are controlled. The main challenge is low-dose hydrochlorothiazide distribution across the blend.

A direct-compression platform should use engineered API particle size, ordered mixing, suitable glidant concentration, and validated segregation controls. Roller compaction is an alternative where powder flow or compressibility is inadequate.

Improved tablet identification

Diovan HCT uses strength-specific color and appearance. A generic can improve medication safety with:

• Clear imprinting.
• High-contrast color coding.
• Distinct shapes by strength.
• Unit-dose packaging.
• Tall-man labeling for valsartan/hydrochlorothiazide.

These changes are usually more valuable in hospital and long-term-care procurement than in retail markets.

Smaller tablets and packaging efficiency

Tablet size reduction can improve adherence and lower packaging cost. It must be balanced against the total mass required for excipients and the compression properties of the selected platform.

A smaller tablet may have commercial value in fixed-dose combination markets where patients already take several antihypertensive medicines.

What FDA regulatory pathway applies to Diovan HCT generics?

The standard pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant generally must show:

• Pharmaceutical equivalence.
• Bioequivalence.
• Appropriate inactive-ingredient safety.
• Conformance with current good manufacturing practice.
• Equivalent strength, dosage form, route, and labeling, subject to permitted differences.

The product is an immediate-release oral tablet, so the development program normally centers on comparative dissolution and in vivo bioequivalence. FDA guidance requires a product-specific approach to study design, strength selection, fed or fasting conditions, and statistical analysis.[8]

A 505(b)(2) application would be less attractive for a conventional tablet because the reference product already supports the ANDA route. It could become relevant for a materially different dosage form, delivery system, or clinically meaningful formulation change, but that route would increase development and regulatory cost.

How strong is the Diovan HCT patent estate?

The historical estate was commercially important. The current estate is weak as a barrier to ordinary U.S. generic tablets.

Patent-estate attribute	Assessment
Blocking power against standard generic tablets	Low
Historical Novartis protection	Strong during active term
Remaining U.S. lifecycle value	Limited
New formulation opportunity	Moderate
Manufacturing-process opportunity	Moderate
International variation	Material
Freedom-to-operate complexity	Moderate

The most valuable IP for a new entrant is unlikely to be a broad Diovan HCT patent. It is more likely to be process know-how, controlled-release or abuse-deterrent technology if developed, packaging architecture, low-moisture manufacturing, or a differentiated combination product.

Which companies compete with Diovan HCT?

The competitive field includes:

• Novartis, as the originator of Diovan HCT.
• Generic manufacturers holding ANDAs for valsartan/hydrochlorothiazide.
• Regional pharmaceutical companies supplying the combination outside the United States.
• Manufacturers of separate valsartan and hydrochlorothiazide tablets.
• Competing fixed-dose combinations such as losartan/hydrochlorothiazide, irbesartan/hydrochlorothiazide, and olmesartan/hydrochlorothiazide.

The commercial substitute is not limited to another fixed-dose combination. Physicians and payers can use separate tablets, other angiotensin receptor blocker/thiazide combinations, ACE inhibitor/thiazide products, or calcium-channel blocker combinations.

What revenue exposure and generic launch opportunities exist?

Novartis does not generally report Diovan HCT revenue as a separate current product line. The company reports broader pharmaceutical and cardiovascular portfolios, so product-level revenue must be estimated from prescription data, tender awards, shipment data, or channel audits rather than relying on public segment reporting.[9]

Commercial opportunities remain in five areas:

1. Multi-source generic supply for U.S. retail and mail-order channels.
2. Government and hospital tenders in price-sensitive markets.
3. Reliable supply of less frequently stocked 320/25 mg and 320/12.5 mg strengths.
4. Lactose-free or moisture-optimized products.
5. Emerging-market fixed-dose combination portfolios.

The most attractive launch strategy is usually a multi-strength filing with manufacturing flexibility. A company that launches only the highest-volume strength may lose formulary access to competitors offering the full strength range.

What generic launch risks exist for valsartan/hydrochlorothiazide?

The principal risks are technical and commercial:

• Hydrochlorothiazide blend uniformity at the 12.5 mg dose.
• Dissolution mismatch caused by lubricant overuse.
• API particle-size variability.
• Moisture-related stability failures.
• Tablet hardness and friability problems after scale-up.
• Inconsistent supply of valsartan API.
• Price erosion after multiple ANDA launches.
• Substitution by other ARB/thiazide combinations.
• Low profitability for low-volume strengths.
• Recalls caused by manufacturing or contamination events.

Valsartan supply-chain risk also has a regulatory history. FDA identified nitrosamine contamination in certain valsartan products and issued recalls beginning in 2018. The episode increased scrutiny of API sources, manufacturing changes, impurity controls, and supplier qualification.[10]

Key Takeaways

• Diovan HCT is a mature valsartan/hydrochlorothiazide fixed-dose combination with limited current U.S. patent-based entry protection.
• The reference tablet uses a conventional excipient system built around lactose, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, and film-coating agents.
• The strongest generic formulation opportunities are moisture protection, direct compression, lactose-free composition, smaller tablets, and improved packaging.
• Low-dose hydrochlorothiazide creates the main blend-uniformity and content-uniformity challenge.
• An ANDA is the preferred U.S. regulatory pathway for a conventional generic tablet.
• Product-specific formulation patents may have value, but the historical Diovan HCT estate is not a broad current barrier to standard generic entry.
• Commercial success depends more on cost, supply reliability, full-strength portfolio coverage, and tender access than on new molecule IP.

FAQs

Can a generic Diovan HCT use different excipients?

Yes. An ANDA may use different inactive ingredients if the formulation meets FDA requirements for safety, quality, pharmaceutical equivalence, dissolution, and bioequivalence.

Is Diovan HCT protected by biologic or biosimilar exclusivity?

No. Valsartan and hydrochlorothiazide are small-molecule active ingredients. Biosimilar rules do not apply.

Is a lactose-free valsartan/hydrochlorothiazide tablet commercially viable?

Yes, but the opportunity is niche. The product would need to preserve bioequivalence while demonstrating a channel-specific benefit in pharmacies, hospitals, or international markets.

Could a new extended-release version obtain separate IP protection?

Potentially. A genuinely differentiated release profile, formulation, or delivery technology could support new patent claims, but it would require a separate regulatory strategy and clinical or bioequivalence justification.

Which Diovan HCT strength is most important for a generic launch?

The 160/12.5 mg strength is generally a core commercial target because it represents a common maintenance combination. A complete portfolio should also address 80/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg where market demand supports the filings.

References

1. Novartis Pharmaceuticals Corporation. (2023). Diovan HCT (valsartan and hydrochlorothiazide) tablets prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. National Library of Medicine. (n.d.). Diovan HCT- valsartan and hydrochlorothiazide tablet. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,399,578: N-substituted aza-bicycloalkane derivatives. https://patents.google.com/patent/US5399578

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

7. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/

8. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development

9. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-reporting

10. U.S. Food and Drug Administration. (2018). FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. https://www.fda.gov/news-events/press-announcements/ valsartan-recall